Triosephosphate isomerase deficiency
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Triosephosphate isomerase deficiency Classification and external resources | |
| ICD-10 | D55.2 |
|---|---|
| ICD-9 | 282.3 |
| OMIM | 190450 |
| DiseasesDB | 30116 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Triosephosphate isomerase deficiency is a rare, autosomal recessive disorder which was initially described in 1965.[1] It is a unique glycolytic enzymopathy that is characterized by chronic haemolytic anaemia, cardiomyopathy, susceptibility to infections, severe neurological dysfunction, and, in most cases, death in early childhood.[1] As mentioned, the disease is exceptionally rare with less than 100 patients diagnosed worldwide. In these patients, thirteen different mutations in the respective gene, which is located at chromosome 12p13 and encodes the ubiquitous housekeeping enzyme triosephosphate isomerase (TPI), have been discovered so far.[1] TPI is a crucial enzyme of glycolysis and catalyzes the interconversion of dihydroxyacetone phosphate and glyceraldehyde-3-phosphate. A marked decrease in TPI activity and an accumulation of dihydroxyacetone phosphate have been detected in erythrocyte extracts of homozygous (two identical mutant alleles) and compound heterozygous (two different mutant alleles) TPI deficiency patients. Remarkably, heterozygous individuals are clinically unaffected, even if their residual TPI activity is reduced. Recent work suggests that not a direct inactivation, but an alteration in TPI dimerization might underlie the pathology.[1] This might explain why the disease is rare, but inactive TPI alleles have been detected at higher frequency implicating a heterozygote advantage of inactive TPI alleles.
References
WikiDoc Research Resources for Triosephosphate isomerase deficiency | |
|---|---|
| Articles on Triosephosphate isomerase deficiency | Most recent articles on Triosephosphate isomerase deficiency • Most cited articles on Triosephosphate isomerase deficiency • Review articles on Triosephosphate isomerase deficiency • Articles on Triosephosphate isomerase deficiency in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Triosephosphate isomerase deficiency | Powerpoint slides on Triosephosphate isomerase deficiency • Images of Triosephosphate isomerase deficiency • Photos of Triosephosphate isomerase deficiency • Podcasts & MP3s on Triosephosphate isomerase deficiency • Videos on Triosephosphate isomerase deficiency |
| Evidence Based Medicine Regarding Triosephosphate isomerase deficiency | Cochrane Collaboration on Triosephosphate isomerase deficiency • Bandolier on Triosephosphate isomerase deficiency • TRIP on Triosephosphate isomerase deficiency |
| Cost Effectiveness of Triosephosphate isomerase deficiency | Cost Effectiveness of Triosephosphate isomerase deficiency |
| Clinical Trials Involving Triosephosphate isomerase deficiency | Ongoing Trials on Triosephosphate isomerase deficiency at Clinical Trials.gov • Trial results on Triosephosphate isomerase deficiency • Clinical Trials on Triosephosphate isomerase deficiency at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding Triosephosphate isomerase deficiency | US National Guidelines Clearinghouse on Triosephosphate isomerase deficiency • NICE Guidance on Triosephosphate isomerase deficiency • NHS PRODIGY Guidance • FDA on Triosephosphate isomerase deficiency • CDC on Triosephosphate isomerase deficiency |
| Textbook Information on Triosephosphate isomerase deficiency | Books and Textbook Information on Triosephosphate isomerase deficiency |
| Pharmacology Resources on Triosephosphate isomerase deficiency | Dosing of Triosephosphate isomerase deficiency • Drug interactions with Triosephosphate isomerase deficiency • Side effects of Triosephosphate isomerase deficiency • Allergic reactions to Triosephosphate isomerase deficiency • Overdose information on Triosephosphate isomerase deficiency • Carcinogenicity information on Triosephosphate isomerase deficiency • Triosephosphate isomerase deficiency in pregnancy • Pharmacokinetics of Triosephosphate isomerase deficiency • |
| Genetics, Pharmacogenomics, and Proteinomics of Triosephosphate isomerase deficiency | Genetics of Triosephosphate isomerase deficiency • Pharmacogenomics of Triosephosphate isomerase deficiency • Proteomics of Triosephosphate isomerase deficiency |
| Newstories on Triosephosphate isomerase deficiency | Triosephosphate isomerase deficiency in the news • Be alerted to news on Triosephosphate isomerase deficiency • News trends on Triosephosphate isomerase deficiency |
| Commentary on Triosephosphate isomerase deficiency | Blogs on Triosephosphate isomerase deficiency |
| Patient Resources on Triosephosphate isomerase deficiency | Patient resources on Triosephosphate isomerase deficiency • Discussion groups on Triosephosphate isomerase deficiency • Patient Handouts on Triosephosphate isomerase deficiency • Directions to Hospitals Treating Triosephosphate isomerase deficiency • Risk calculators and risk factors for Triosephosphate isomerase deficiency |
| Healthcare Provider Resources on Triosephosphate isomerase deficiency | Symptoms of Triosephosphate isomerase deficiency • Causes & Risk Factors for Triosephosphate isomerase deficiency • Diagnostic studies for Triosephosphate isomerase deficiency • Treatment of Triosephosphate isomerase deficiency |
| Continuing Medical Education (CME) Programs on Triosephosphate isomerase deficiency | CME Programs on Triosephosphate isomerase deficiency |
| International Resources on Triosephosphate isomerase deficiency | Triosephosphate isomerase deficiency en Espanol • Triosephosphate isomerase deficiency en Francais |
| Business Resources on Triosephosphate isomerase deficiency | Triosephosphate isomerase deficiency in the Marketplace • Patents on Triosephosphate isomerase deficiency |
| Informatics Resources on Triosephosphate isomerase deficiency | List of terms related to Triosephosphate isomerase deficiency |
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
